BNTC: Utang marang Ekuitas benitec.com

Lambang korporat lan logo Benitec Biopharma (BNTC)

The confirmed price history on the chart shows that the total debt-to-equity ratio is 0.00, while drug production is delegated to external certified partners. Benitec Biopharma Inc. (BNTC) is developing RNA interference methods to combat rare diseases, including OPMD. The business strategy relies on building a portfolio of innovative gene-silencing solutions, which effectively minimizes scientific risks within the field of genetic engineering.

BNTC: Total Utang marang Modal benitec.com 04.07.2022 - 30.10.2026

Rincian metrik lan analitis perusahaan Benitec Corp (BNTC)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Benitec Biopharma|BNTC - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Nilai pasar Benitec Biopharma|BNTC - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham Benitec Biopharma|BNTC - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku benitec.com|BNTC - Aset Agregat Perusahaan
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal Benitec Biopharma Inc.|BNTC - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Benitec Biopharma Inc.|BNTC - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Benitec Biopharma|BNTC - Gunggunge utang jangka dawa|Kewajiban jangka cendhak perusahaan Benitec Biopharma|Rasio cepet benitec.com
- informasi bathi lan kelipatan valuasi:
BNTC - Penghasilan resik perusahaan
Analisis umum perusahaan:Benitec Biopharma, BNTC
Produk dadi Benitec Biopharma Inc.

The financial stability of Benitec Biopharma Inc. (BNTC) is determined by the balance between attracting investment and maintaining autonomy. This metric compares total liabilities with net assets, revealing the degree of dependence on creditors. It measures bankruptcy risk by assessing the proportion of borrowed funds within the capital structure. For a company in the clinical trial phase of ddRNAi drugs, this is a critical marker of solvency. By analyzing the current debt-to-equity ratio, an investor determines the safety of the business expansion.

Analisis pesaing

TEM (tempus.com) - Total Utang marang Modal|Rasio Utang marang Ekuitas QGEN (Qiagen NV)|Utang marang Ekuitas Ionis Pharma (IONS)|Repligen Inc. - Rasio Utang marang Ekuitas|Total Utang marang Modal RNA (Avidity Biosciences)|Total Utang marang Modal crisprtx.com CRSP|GeneDx - Total Utang marang Modal|RARE: Utang marang Ekuitas|BEAM: Total Utang marang Modal|Utang marang Modal Sarepta Corp (SRPT)|Utang marang Ekuitas Twist Bioscience|Rasio Utang marang Ekuitas TXG (10xgenomics.com)|Total Utang marang Modal NTLA|Koefisien Total Utang marang Modal Stoke Therapeutics Inc|BioLife Corp - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal WVE (Wave Pharma)|Maze Therapeutics Inc - Total Utang marang Modal|Utang marang Modal sionnatx.com|PRME: Total Utang marang Modal|Rasio Total Utang marang Ekuitas Taysha Gene Therapies Inc|Rasio Total Utang marang Ekuitas QURE|MGTX: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal RGNX|Utang marang Ekuitas SLDB (solidbio.com)|Total Utang marang Modal OCGN (Ocugen)|Koefisien Total Utang marang Modal Pacific Biosciences of California, Inc. (PACB)|DSGN - Utang marang Ekuitas|Utang marang Modal Rocket Corp|4D Molecular Therapeutics (FDMT) - Utang marang Ekuitas|Utang Agregat marang Ekuitas LXEO (Lexeo Therapeutics, Inc.)|KRRO (Korro Bio Inc.) - Total Utang marang Modal|EDIT: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLN|Total Utang marang Modal proqr.com (PRQR)|Utang marang Ekuitas Codexis CDXS|Rasio Kabeh Utang marang Dana Pribadi SGMO|NAUT - Utang marang Ekuitas|Metagenomi Inc. (MGX) - Rasio Total Utang marang Ekuitas|DTIL: Total Utang marang Modal|Generation Bio (GBIO) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas BOLD|XCUR: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal IMNN|Koefisien Total Utang marang Modal phiopharma.com|Utang marang Ekuitas Mustang Bio MBIO|RNAZ: Rasio Utang marang Ekuitas|Bionano - Total Utang marang Modal|adnas.com (APDN) - Rasio Total Utang marang Ekuitas|BLUE (bluebird bio) - Rasio Total Utang marang Ekuitas|IPA - Koefisien Total Utang marang Modal|OMGA (Omega) - Total Utang marang Modal|Utang marang Ekuitas OMIC|Utang marang Ekuitas Regulus Therapeutics (RGLS)|syros.com - Rasio Utang marang Ekuitas|Telesis Bio - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal TCON (TRACON Pharmaceuticals Inc.)|Unity Bio - Total Utang marang Modal